Home research company Braxia Scientific Announces Voting Results of Annual and Extraordinary General Meeting of Shareholders

Braxia Scientific Announces Voting Results of Annual and Extraordinary General Meeting of Shareholders


TORONTO, November 1, 2022 /PRNewswire/ – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics offering innovative ketamine and psilocybin treatments for Depression and Related Disorders, is pleased to announce the voting results of its Annual General and Special Meeting of Shareholders held on Monday, October 31, 2022. A total of 16.55% of the common shares issued and in circulation of the Company were represented either in person or by proxy at the meeting.

In a vote by ballot, the following 4 candidates proposed by the Company were elected directors of Braxia Scientific to serve until the next annual meeting of shareholders of the Company or until their successors are elected or appointed, the shares represented at the meeting voting in favor of individual nominees as follows:






Roger McIntyre

39 392 336




Olga Cwiek





Lean Taylor



452 254


Jerry Habuda





In addition to the election of all nominees listed as directors in the management information circular dated September 16, 2022 (the “Circular”), Braxia shareholders have approved all other resolutions submitted to the Meeting. These included the appointment of DMCL as auditors of the Company for the following year and the approval of an amendment to the Company’s stock option plan dated October 15, 2019 as indicated in the Circular.

For more details on the matters discussed at the annual meeting, please consult the Company’s management information circular available on SEDAR at www.sedar.com. Final voting results on all matters to be voted on at the annual meeting will also be filed on SEDAR.

About Braxia Scientific Corp.

Braxia Scientific is a medical research company with clinics that provide innovative ketamine-based treatments for people with depression and related disorders. Through its medical solutions, Braxia aims to reduce the disease burden of brain-based mental disorders such as major depressive disorder, among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to the discovery and commercialization of new drugs and methods. administration. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly-owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community clinics offering fast-acting treatments for depression located in Mississauga, Toronto, Ottawa, Kitchener and Montreal. For more information, visit www.braxiascientific.com Where www.braxiahealth.com.


“dr. Roger S. McIntyre
dr. Roger S. McIntyre


The CSE has not reviewed and accepts no responsibility for the accuracy or adequacy of this release.

Forward-looking information Disclaimer
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, goals, assumptions, expectations or beliefs regarding future performance are “forward-looking statements”.

Forward-looking statements include statements about the expected promise of ketamine-based treatments for depression and the potential of ketamine to treat other emerging psychiatric disorders, such as bipolar depression. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, the inability of ketamine, psilocybin, and other psychedelics to provide expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals , including acquiring and renewing federal, state, municipal, local or other licenses and engaging in activities that may subsequently be deemed illegal under national or international law. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, SC 1996, c. 19 (the “CDSA”) and possession of such substances under the CDSA without a prescription or legal exemption is a criminal offence. Health Canada has not approved psilocybin as a drug for any indication, but ketamine is a legally authorized drug for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without prescription. These factors should be carefully considered and readers are cautioned not to place undue reliance on these forward-looking statements.

Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in the forward-looking statements, there may be other risk factors that cause the actions, events or results differ from those anticipated, estimated or expected. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, including the amended and restated registration statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in the forward-looking statements.

SOURCE Braxia Scientific Corp.